| Not Yet Recruiting | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Im NCT06882174 | AHS Cancer Control Alberta | Phase 2 |
| Not Yet Recruiting | An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary NCT07461727 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemother NCT07222566 | Pfizer | Phase 3 |
| Recruiting | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor a NCT07185997 | ArriVent BioPharma, Inc. | Phase 3 |
| Recruiting | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing NCT06066138 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | MOv19-BBz CAR T Cells in FRa+ Cancers NCT07116057 | University of Pennsylvania | Phase 1 |
| Recruiting | Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell NCT07008742 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer NCT06863233 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC NCT06068153 | ETOP IBCSG Partners Foundation | Phase 2 |
| Recruiting | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer NCT06731413 | Virginia Commonwealth University | Phase 2 |
| Active Not Recruiting | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Tre NCT07024862 | Bristol-Myers Squibb | — |
| Recruiting | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum NCT06417814 | AstraZeneca | Phase 3 |
| Recruiting | Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer NCT06523673 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Recruiting | The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients NCT06428422 | Necmettin Erbakan University | N/A |
| Recruiting | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301 | NovoCure GmbH | Phase 3 |
| Recruiting | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer NCT06343402 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Terminated | C-TIL051 in Non-Small Cell Lung Cancer NCT05676749 | AbelZeta Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613 | Obsidian Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Particip NCT05984277 | AstraZeneca | Phase 3 |
| Recruiting | Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti- NCT05985330 | Centre Hospitalier Universitaire Dijon | — |
| Active Not Recruiting | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous NCT06212752 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic NCT05607550 | ArriVent BioPharma, Inc. | Phase 3 |
| Active Not Recruiting | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Ca NCT05635708 | BeiGene | Phase 2 |
| Active Not Recruiting | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous NCT05722015 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | CISH Inactivated TILs in the Treatment of NSCLC NCT05566223 | Intima Bioscience, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell NCT05555732 | Daiichi Sankyo | Phase 3 |
| Unknown | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic NCT05259319 | Centre Georges Francois Leclerc | Phase 1 |
| Completed | Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung C NCT07192926 | Ankara Etlik City Hospital | — |
| Active Not Recruiting | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activat NCT05364073 | ArriVent BioPharma, Inc. | Phase 1 |
| Completed | A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) NCT05546905 | Pierre Fabre Medicament | — |
| Completed | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) NCT05429320 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembroliz NCT05226598 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advan NCT05215340 | Daiichi Sankyo | Phase 3 |
| Active Not Recruiting | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic N NCT04743505 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Unknown | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced NCT05111197 | Institut Cancerologie de l'Ouest | Phase 3 |
| Completed | Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment NCT05167500 | Fundación GECP | — |
| Unknown | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC NCT05236608 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell NCT04884282 | Fondazione Ricerca Traslazionale | Phase 2 |
| Completed | Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and NCT05675683 | Novartis Pharmaceuticals | — |
| Completed | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) NCT04965090 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Dupilumab_Metastatic NSCLC NCT05013450 | Thomas Marron | Phase 1 / Phase 2 |
| Recruiting | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer NCT04614103 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (N NCT04863248 | G1 Therapeutics, Inc. | Phase 2 |
| Completed | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel NCT04725188 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC NCT05223595 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KR NCT04685135 | Mirati Therapeutics Inc. | Phase 3 |
| Active Not Recruiting | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemot NCT04623775 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib NCT04613596 | Mirati Therapeutics Inc. | Phase 2 / Phase 3 |
| Unknown | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446 | Blueprint Medicines Corporation | — |
| Completed | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating NCT04511533 | Pfizer | Phase 4 |
| Recruiting | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers NCT04410796 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC NCT05278052 | Tata Memorial Hospital | Phase 3 |
| Active Not Recruiting | Plasma-Adapted First-Line Pembro In NSCLC NCT04166487 | Julia K. Rotow, MD | Phase 2 |
| Completed | A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases NCT03497767 | Trans Tasman Radiation Oncology Group | Phase 2 |
| Unknown | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib NCT03976856 | Genor Biopharma Co., Ltd. | Phase 1 |
| Completed | Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA NCT03926260 | Centre Hospitalier Departemental Vendee | N/A |
| Completed | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants W NCT03976375 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer NCT03810807 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) NCT03679767 | Incyte Corporation | Phase 2 |
| Terminated | A Study of ADXS-NEO Expressing Personalized Tumor Antigens NCT03265080 | Advaxis, Inc. | Phase 1 |
| Terminated | PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients NCT03436056 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NS NCT03164772 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Completed | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer NCT03215810 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. NCT03224871 | University of California, Davis | EARLY_Phase 1 |
| Completed | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC NCT03004183 | The Methodist Hospital Research Institute | Phase 2 |
| Unknown | Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCL NCT03300115 | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Phase 2 |
| Completed | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Meta NCT02857270 | Eli Lilly and Company | Phase 1 |
| Completed | PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer NCT02793856 | Sichuan University | Phase 1 |
| Completed | Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy NCT02705820 | Bank of Cyprus Oncology Centre | Phase 2 |
| Completed | Universal Cancer Peptide-based Vaccination in Metastatic NSCLC NCT02818426 | Centre Hospitalier Universitaire de Besancon | Phase 1 / Phase 2 |
| Withdrawn | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer NCT02639234 | Gradalis, Inc. | Phase 2 |
| Withdrawn | Abscopal Effect for Metastatic Non-small Cell Lung Cancer. NCT02542930 | Zhejiang Provincial People's Hospital | Phase 2 |
| Active Not Recruiting | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGF NCT02411448 | Eli Lilly and Company | Phase 3 |
| Unknown | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC NCT02330367 | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors NCT01936961 | Western Regional Medical Center | N/A |
| Completed | Etirinotecan Pegol (NKTR-102) in NSCLC NCT01773109 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Sma NCT01395758 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 |
| Unknown | Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients NCT01717105 | Grupo Gallego de Cancer de Pulmon | — |
| Terminated | Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer NCT01060514 | Northwestern University | Phase 1 |
| Completed | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] NCT06585189 | Aetion, Inc. | — |
| Terminated | A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases NCT00872482 | YM BioSciences | Phase 2 |
| Completed | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non NCT00806286 | Daiichi Sankyo | Phase 2 |
| Approved For Marketing | Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer NCT04599712 | Janssen Research & Development, LLC | — |